<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Terzah M Horton, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie R Park, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Newburger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) is the most common malignancy in children, accounting for one-third of all childhood cancers. The term ALL/LBL is used because the current system for diagnosis and classification does not distinguish between clinical presentations as leukemia or lymphoma [<a href="#rid1">1</a>]; by convention, the term lymphoma is used when it is confined to a mass lesion with little or no blood and marrow involvement. </p><p>Outcomes for pediatric ALL/LBL have improved dramatically since the 1980s, with approximately 90 percent five-year overall survival [<a href="#rid2">2-4</a>]. Improved outcomes and reduced toxicity are related to widespread adoption of standardized research protocols, improved prevention/treatment of leukemic meningitis, and risk-based stratification of treatment.</p><p>This topic discusses prognostic features and risk stratification for ALL/LBL in children, adolescents, and young adults.</p><p>Clinical presentation, classification, treatment, and outcomes of childhood ALL/LBL are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6244.html" rel="external">"Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"</a> and  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p class="headingAnchor" id="H3664410988"><span class="h1">PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>In pediatric ALL/LBL, the immunophenotype and cytogenetic/molecular findings of leukemic blasts are associated with clinical outcomes and are used to categorize ALL/LBL  (<a class="graphic graphic_table graphicRef110239" href="/z/d/graphic/110239.html" rel="external">table 1</a>). Response to therapy and certain clinical features are also associated with prognosis. Cooperative groups use different clinical, biologic, and disease-response criteria to allocate patients to as many as five prognostic categories [<a href="#rid5">5-7</a>]. </p><p class="headingAnchor" id="H321167952"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Age, white blood cell (WBC) count, and involvement of the central nervous system (CNS) or testes at diagnosis are standard criteria used by cooperative groups for risk assignment in pediatric ALL/LBL  (<a class="graphic graphic_table graphicRef71649" href="/z/d/graphic/71649.html" rel="external">table 2</a>) [<a href="#rid8">8-10</a>]. Age and WBC count are important prognostic features for B cell ALL/LBL but are less predictive for T cell ALL/LBL [<a href="#rid11">11,12</a>]. </p><p>As treatment has improved, clinical features that were formerly used to categorize patients are no longer independently associated with treatment outcomes. Examples of factors that are no longer used to stratify treatment include sex; race/ethnicity; presence of a mediastinal mass, organomegaly, or lymphadenopathy; and hemoglobin, platelet count, and serum immunoglobulin levels [<a href="#rid13">13,14</a>]. Adverse outcomes associated with race (Black) and ethnicity (Hispanic) have, instead, been linked to socioeconomic factors and/or genomic variations (eg, Hispanic children are more likely to have somatic <em>CRLF2</em> rearrangements) [<a href="#rid15">15-17</a>]. </p><p>Use of clinical features for risk stratification in pediatric ALL/LBL is described below. (See <a class="local">'Risk stratification'</a> below.)</p><p class="headingAnchor" id="H654339928"><span class="h3">Age</span><span class="headingEndMark"> — </span>Patients ≥10 years or ≤1 year have less favorable outcomes and are assigned to higher risk groups [<a href="#rid8">8-10</a>].</p><p>Age at presentation is associated with certain cytogenetic/molecular features. As examples, infants are more likely than others to have rearrangements involving <em>KMT2A</em> (<em>MLL</em>) [<a href="#rid18">18,19</a>], while adolescents are more likely to have certain adverse molecular findings (eg, <em>BCR::ABL1</em> rearrangement, Ph-like ALL/LBL) and less likely to have low-risk subtypes (hyperdiploidy, <em>ETV6::RUNX1</em> rearrangement).</p><p class="headingAnchor" id="H2540311838"><span class="h3">Infant ALL/LBL</span><span class="headingEndMark"> — </span>ALL/LBL in infants has distinct biological characteristics and prognosis. Approximately three-quarters of infants with ALL/LBL have translocations involving 11q23 at the <em>KMT2A</em> gene locus [<a href="#rid20">20-23</a>]. (See  <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 't(v;11q23.3)'</a>.)</p><p>Translocations of 11q23 involve rearrangements of <em>KMT2A</em> with one of numerous partner genes; the resultant fusion products drive distinct patterns of gene expression [<a href="#rid1">1,24</a>]. Infant ALL/LBL typically presents as B cell precursor blasts with coexpression of myeloid markers; as a result, <em>KMT2A</em> was previously called mixed-lineage leukemia (<em>MLL</em>). </p><p>Diagnosis of ALL/LBL in the first three months of life is associated with particularly poor prognosis [<a href="#rid25">25,26</a>]. Infants with ALL/LBL are typically treated with more aggressive chemotherapy because they have poor responses to conventional therapy [<a href="#rid25">25,27-29</a>]. Compared with pediatric ALL/LBL with nonrearranged <em>KMT2A</em>,<em> </em>infant ALL/LBL is associated with high rates of early treatment failure and poor outcomes [<a href="#rid21">21,22,24,25,30,31</a>]. As an example, in a series of 147 infants, the estimated five-year event-free survival (EFS) rate in infants with ALL/LBL and a <em>KMT2A</em> rearrangement was 19 percent compared with 46 percent five-year EFS for others [<a href="#rid31">31</a>]. </p><p class="headingAnchor" id="H2391449897"><span class="h3">White blood cell count</span><span class="headingEndMark"> — </span>WBC count &gt;50,000/microL at presentation has long been associated with inferior outcomes in ALL/LBL [<a href="#rid5">5,11</a>]. All cooperative groups use hyperleukocytosis as a criterion for a higher-risk category  (<a class="graphic graphic_table graphicRef71649" href="/z/d/graphic/71649.html" rel="external">table 2</a>). </p><p class="headingAnchor" id="H1621872590"><span class="h3">Central nervous system or testicular involvement</span><span class="headingEndMark"> — </span>Involvement of the CNS or testes at diagnosis is an adverse prognostic feature  (<a class="graphic graphic_table graphicRef71649" href="/z/d/graphic/71649.html" rel="external">table 2</a>). </p><p>All children who present with ALL/LBL should undergo an initial diagnostic lumbar puncture (LP). In addition, boys should have a pretreatment testicular examination for a mass or swelling. Pretreatment evaluation of ALL/LBL and interpretation of findings from the initial LP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Pretreatment evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Lumbar puncture'</a>.)</p><p>Detection of blasts in the cerebrospinal fluid (CSF) with the initial LP is associated with an inferior outcome [<a href="#rid8">8-10</a>]. After adjusting for other prognostic factors, the presence of CSF blasts at diagnosis is associated with inferior outcomes, even for patients with low levels of CNS involvement [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H1882750350"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>B cell ALL/LBL accounts for a large majority of pediatric ALL/LBL. T cell ALL/LBL is less common and is associated with inferior prognosis.</p><p>Burkitt lymphoma/leukemia, which is a malignancy with a mature B cell phenotype that is associated with t(8;14) translocation, is not considered a category of ALL/LBL in the current World Health Organization (WHO) classification scheme [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma"</a>.)</p><p class="headingAnchor" id="H746842355"><span class="h3">T cell</span><span class="headingEndMark"> — </span>T cell immunophenotype accounts for up to 15 percent of newly diagnosed pediatric ALL/LBL and has distinctive clinical and biological features. For pediatric T cell ALL/LBL, the response to initial treatment is a more important prognostic determinant than clinical and laboratory features. (See <a class="local">'T cell ALL/LBL'</a> below.)</p><p>Historically, T cell ALL/LBL was considered an adverse prognostic feature, but use of more intensive treatments has been associated with outcomes that approach those with B cell ALL/LBL [<a href="#rid33">33-36</a>]. It is uncertain if inferior outcomes are intrinsic to the T cell immunophenotype, or if they relate to its association with other adverse clinical features (eg, increased age, leukocytosis) [<a href="#rid37">37-41</a>], since younger patients with the T cell immunophenotype who do not have high WBC counts or bulky disease have done well using either T cell-specific regimens or protocols for higher-risk ALL/LBL [<a href="#rid40">40,42,43</a>]. Gene expression profiling may be useful for identifying patients with T cell ALL/LBL at higher risk for induction failure, relapse, and/or inferior overall survival (OS) [<a href="#rid44">44-46</a>], but this requires validation in larger studies.</p><p>Most cases of T cell ALL/LBL are associated with one of three pathophysiologic mechanisms: abnormal T lineage transcription factors, aberrant NOTCH1/MYC signaling, or altered cell-cycle control [<a href="#rid10">10</a>]. Prognosis is not associated with the specific molecular features of T cell ALL/LBL. Examples of abnormalities of T lineage transcription factors include rearrangement with T cell receptor (<em>TCR</em>) enhancers, structural variants, or enhancer mutations of <em>TAL1, TAL2, TLX1, TLX, HOXA, LMO1/LMO2, LMO2/LYL1,</em> or<em> NKX2-1</em> [<a href="#rid47">47-49</a>]. Aberrant activation of NOTCH1 (a critical transcription factor for T cell development) promotes uncontrolled cell growth, partly through increased MYC expression; this is associated with activating <em>NOTCH1</em> mutations in three-quarters of cases and with loss-of-function mutations of <em>FBXW7</em> in others [<a href="#rid50">50-52</a>]. Deletion of the tumor suppressors, <em>CDKN2A/CDKN2B</em>, <em>CDKN1B, RB1, </em>or<em> CCND3</em> can alter cell cycle control [<a href="#rid48">48,53</a>]. Less often, T cell ALL/LBL is associated with abnormal signaling (eg, activated PI3K-AKT through loss of PTEN) or derangement of MYB, LEF1, or BCL11B; ribosomal function; ubiquitination; RNA processing; epigenetic modifiers, and other mechanisms [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 'T-ALL/LBL'</a>.)</p><p class="headingAnchor" id="H930935949"><span class="h3">Early T cell precursor</span><span class="headingEndMark"> — </span>Early T cell precursor (ETP) ALL/LBL is a subcategory (12 to 15 percent) of T cell ALL/LBL that is characterized by a distinct immunophenotype. ETP blasts lack expression of CD1a and CD8, have weak or negative CD5 expression, and express one or more myeloid or stem cell markers; the same immunophenotype, but with stronger CD5 expression, has been called near-ETP [<a href="#rid54">54</a>].</p><p>ETP ALL/LBL often manifests slow treatment response; in some, but not all, studies ETP ALL/LBL has been associated with inferior outcomes. The Children’s Oncology Group (COG) AALL0434 trial of 1256 children, adolescents, and young adults with T cell ALL/LBL reported that patients with ETP and near-ETP subtypes had higher rates of induction failure than patients with non-ETP disease T cell ALL/LBL (6 versus 1 percent), but the three groups had similar five-year OS (87 to 90 percent) [<a href="#rid55">55</a>]. Another cooperative group study that included 35 cases of ETP ALL/LBL reported no difference in EFS compared with non-ETP T cell ALL/LBL [<a href="#rid56">56</a>]. A single-institution study of 38 children with ETP ALL/LBL reported inferior outcomes in this subtype of T cell ALL/LBL [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Cytogenetics</span><span class="headingEndMark"> — </span>Cytogenetic features are important for classification of ALL/LBL in the WHO scheme  (<a class="graphic graphic_table graphicRef110239" href="/z/d/graphic/110239.html" rel="external">table 1</a>) [<a href="#rid1">1,58</a>], as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma"</a>.)</p><p>Prognosis is associated with abnormal structural features of chromosomes (eg, translocations) and with aneuploidy (eg, hypodiploidy or hyperdiploidy). In a study of 1725 children with B cell ALL/LBL, favorable outcomes were associated with high hyperdiploidy<strong> </strong>(&gt;50 chromosomes), while iAMP21, t(9;22), 11q23 translocation, abnormal 17p, and loss of 13q were associated with increased risk for relapse [<a href="#rid59">59</a>]. </p><p class="headingAnchor" id="H476192560"><span class="h3">High hyperdiploidy</span><span class="headingEndMark"> — </span>The presence of ≥50 chromosomes is a favorable prognostic feature [<a href="#rid13">13,60-63</a>]. Among patients with high hyperdiploidy, the best outcomes are associated with double trisomies of chromosomes 4 and 10, or triple trisomies of chromosomes 4, 10, and 17 [<a href="#rid64">64</a>]. As a result, patients with trisomies of these chromosomes do not require intensification of therapy.</p><p>Although rare cases with near-triploidy (68 to 80 chromosomes) or near-tetraploidy (&gt;80 chromosomes) have been associated with poor outcomes [<a href="#rid65">65</a>], a large series reported favorable outcomes in B-lineage ALL/LBL [<a href="#rid66">66</a>]. Care must be used to assure that near-triploidy or near-tetraploidy are not near-haploid or diploid, which have a very poor prognosis [<a href="#rid67">67</a>]. </p><p class="headingAnchor" id="H794026437"><span class="h3">Hypodiploidy</span><span class="headingEndMark"> — </span>The presence of &lt;44 chromosomes is an adverse prognostic indicator, and the likelihood of a poor outcome increases with decreasing numbers of chromosomes. </p><p>Definitions for categories of hypodiploidy vary, but cases lacking only a single chromosome have a prognosis similar to that of diploid cases, whereas cases with fewer chromosomes are associated with inferior outcomes [<a href="#rid60">60,68,69</a>]. In one study, low hypodiploid (32-39 chromosomes) cases are associated with tumor and germline <em>TP53</em> mutations (91 percent), tumor <em>IKAROS</em> mutations (53 percent), and tumor RB1 abnormalities (41 percent) [<a href="#rid70">70</a>]; near haploid (&lt;31 chromosomes) cases are also associated with <em>TP53</em> and <em>RAS</em> mutations (70 percent). Both groups are chemotherapy resistant and require more aggressive chemotherapy.</p><p class="headingAnchor" id="H8"><span class="h2">Structural abnormalities</span><span class="headingEndMark"> — </span>Structural chromosomal abnormalities include translocations, deletions, insertions, and inversions. </p><p class="headingAnchor" id="H3008544993"><span class="h3">t(12;21)/ETV6::RUNX1</span><span class="headingEndMark"> — </span>The t(12;21) translocation is the most common translocation in pediatric ALL/LBL (25 percent of cases) and in many cases it is associated with a favorable prognosis. The t(12;21) translocation creates the <em>ETV6::RUNX1</em> fusion gene (formerly known as <em>TEL::AML1</em>). Patients with this finding do not require treatment intensification. While late relapses are more common with this finding, these patients have an excellent response rate to chemotherapy following relapse [<a href="#rid71">71,72</a>]. Patients with <em>ETV::RUNX1</em> mutations in association with a complex karyotype have a standard risk assessment and treatment varies according to the specific protocol [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 't(12;21)(p13.2;q22.1); ETV6::RUNX1'</a>.)</p><p class="headingAnchor" id="H3978397627"><span class="h3">t(9;22)/BCR::ABL1</span><span class="headingEndMark"> — </span>The t(9;22) translocation (the so-called Philadelphia chromosome [Ph]) is found in 4 percent of ALL/LBL cases; it can found in either B cell or T cell ALL/LBL and is associated with poor prognosis [<a href="#rid74">74</a>]. The t(9;22) translocation creates the <em>BCR::ABL1</em> fusion gene, which encodes a constitutively active tyrosine kinase. Patients with Ph+ ALL/LBL receive higher intensity treatments, including the use of a tyrosine kinase inhibitor (TKI; eg, <a class="drug drug_pediatric" data-topicid="12618" href="/z/d/drug information/12618.html" rel="external">imatinib</a> or <a class="drug drug_pediatric" data-topicid="120511" href="/z/d/drug information/120511.html" rel="external">dasatinib</a>), which has improved outcomes [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 't(9;22); BCR::ABL1'</a>.)</p><p class="headingAnchor" id="H4160250553"><span class="h3">Ph-like (BCR::ABL1-like )</span><span class="headingEndMark"> — </span>This category of ALL/LBL exhibits gene expression profiles and outcomes that resemble those with <em>BCR::ABL1</em>, but the leukemic cells do not express the BCR::ABL1<em> </em>protein; it is also referred to as <em>BCR::ABL1</em>-like B cell ALL/LBL [<a href="#rid76">76,77</a>]. </p><p>Ph-like ALL/LBL is three- to fourfold more common than Ph+ ALL/LBL and has worse outcomes than other high-risk ALL/LBL [<a href="#rid78">78</a>]. Ph-like ALL/LBL often has activated cytokine receptor genes and/or altered kinase signaling pathways and may be amenable to treatment with a TKI [<a href="#rid79">79</a>]. Half of these patients overexpress <em>CRLF2</em>, of which half have a <em>JAK</em> mutation, which may respond to JAK or STAT inhibitors, but treatment with <a class="drug drug_pediatric" data-topicid="122146" href="/z/d/drug information/122146.html" rel="external">ruxolitinib</a> or other JAK inhibitors is not yet considered to be standard of care in pediatric ALL/LBL [<a href="#rid80">80</a>]. Other cases have<em> </em>abnormalities of<em> ABL1, EPOR</em> (erythropoietin receptor), or other kinases [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 'BCR::ABL1-like B cell ALL'</a>.)</p><p class="headingAnchor" id="H4271174311"><span class="h3">iAMP21</span><span class="headingEndMark"> — </span>Intrachromosomal amplification of chromosome 21 (iAMP21) is found in approximately 2 percent of children with B cell ALL/LBL and is associated with a high risk of relapse when treated with less aggressive chemotherapy [<a href="#rid59">59,81,82</a>]. In a retrospective analysis, treatment intensification was associated with improved outcomes; compared with standard treatment, use of more intensive therapy for children with iAMP21 was associated with superior five-year OS (89 versus 67 percent), EFS (78 versus 29 percent), and fewer relapses (16 versus 70 percent) [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 'iAMP21'</a>.)</p><p class="headingAnchor" id="H3115319337"><span class="h3">11q23/KMT2A</span><span class="headingEndMark"> — </span>Rearrangements of 11q23 are found in approximately 10 percent of children with ALL/LBL overall but &gt;70 percent in infants. (See <a class="local">'Infant ALL/LBL'</a> above.)</p><p>11q23 abnormalities are associated with rearrangements of <em>KMT2A</em> and poor prognosis [<a href="#rid83">83</a>]. The leukemic cells are pro-lymphocytes that lack CD10 expression and are often drug resistant (eg, to steroids and asparaginase) [<a href="#rid84">84</a>]. Relapse is common and often involves a lineage switch to acute myeloid leukemia (AML) [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 't(v;11q23.3)'</a>.)</p><p class="headingAnchor" id="H2195027415"><span class="h2">Response to treatment/MRD</span><span class="headingEndMark"> — </span>Early response to chemotherapy is the most important prognostic factor for pediatric ALL/LBL. The standard method for evaluating response to treatment is assessment of measurable residual disease (MRD) by flow cytometry or molecular techniques. Serial, quantitative assessment of MRD indicates the disappearance and reappearance of marrow blasts, which can predict relapse and is incorporated in contemporary pediatric ALL/LBL treatment protocols. </p><p>Most bone marrow aspirates performed at the end-of-induction (EOI) therapy reveal a histologic complete remission (CR; ie, &lt;5 percent lymphoblasts with evidence of hematopoietic recovery). A proportion of children will later relapse, indicating that small numbers of leukemic lymphoblasts persisted in marrow despite the histologic CR. Assessment of MRD enables identification of patients with residual leukemic blasts who may benefit from more intensive chemotherapy. In T cell ALL/LBL, MRD is assessed at both EOI and at the end of consolidation (EOC); the presence of EOC MRD is used for risk stratification and treatment determination [<a href="#rid33">33</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRD methods</strong> – MRD can be measured by flow cytometry (for leukemia-specific aberrant immunophenotypes) or by polymerase chain reaction (PCR) and/or next-generation sequencing (NGS) to detect unique immunoglobulin<em> </em>(<em>Ig</em>) and T cell receptor (<em>TCR</em>) genes or leukemia-specific transcripts (eg, <em>BCR::ABL1</em>). Molecular methods routinely detect one ALL cell among 10⁴ to 10⁵ cells; by comparison, flow cytometry is about 1 log less sensitive for detecting MRD [<a href="#rid86">86,87</a>]. Nevertheless, there is a high correlation in results from molecular and immunophenotypic studies [<a href="#rid88">88-91</a>].</p><p></p><p class="bulletIndent1">MRD is assessed at EOI; if MRD is positive at EOI, it is again assessed at EOC [<a href="#rid92">92-96</a>]. The preferred technique for detecting MRD and its timing vary with the immunologic and molecular features of the individual case and according to the dictates of the cooperative group or clinical protocol. (See  <a class="medical medical_review" href="/z/d/html/4519.html" rel="external">"Clinical use of measurable residual disease detection in acute lymphoblastic leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic impact of MRD</strong> – MRD is the most powerful prognostic factor for pediatric ALL/LBL in all age groups, including patients in low-risk categories [<a href="#rid97">97-105</a>]. In general, patients with favorable genetic subtypes clear MRD faster than those with high-risk genetics and T cell ALL/LBL [<a href="#rid106">106</a>], but the relapse risk at a given level of MRD differs between genetic subtypes [<a href="#rid94">94,95</a>]. </p><p></p><p class="bulletIndent1">Large studies of pediatric ALL/LBL that incorporated prospective MRD monitoring confirmed that long-term relapse-free survival is directly related to the level of residual disease, both early in the course of treatment [<a href="#rid92">92,97,98,107-112</a>] and at later time points [<a href="#rid96">96,98,99,113,114</a>]. </p><p></p><p>In addition to the prognostic value of MRD status, the rate of disappearance of blasts is associated with outcomes. In one trial, 2090 children with ALL/LBL were randomly assigned to receive either standard or intensified therapy, independent of risk factors [<a href="#rid13">13</a>]. In multivariate analysis, after controlling for age, sex, and WBC count, the only significant predictors of outcome were bone marrow blast percentage on day 8 of induction therapy, remission status at EOI, and blast karyotype; the effects of these risk factors were similar in both treatment groups. Other studies support early response to therapy (eg, day 8 MRD in peripheral blood) as an independent prognostic factor [<a href="#rid107">107,115-119</a>].</p><p>Roles for MRD in management of ALL/LBL are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4499.html" rel="external">"Detection of measurable residual disease in acute lymphoblastic leukemia/lymphoblastic lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4519.html" rel="external">"Clinical use of measurable residual disease detection in acute lymphoblastic leukemia"</a> and  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Response assessment'</a>.)  </p><p class="headingAnchor" id="H3440081755"><span class="h1">RISK STRATIFICATION</span><span class="headingEndMark"> — </span>Risk-stratified therapy enables reduced treatment intensity and less toxicity in low-risk patients, while supporting more aggressive therapy for those with a high risk of relapse. Risk-based treatment, along with routine use of clinical trials and introduction of preventive central nervous system (CNS) therapy have contributed to improved survival rates for children with ALL/LBL. </p><p>Clinical features (eg, initial white blood cell [WBC] count, age, CNS or testicular involvement), cytogenetic/molecular findings, immunologic subtype, and rapidity and degree of cytoreduction are used to stratify treatment of ALL/LBL  (<a class="graphic graphic_table graphicRef71649" href="/z/d/graphic/71649.html" rel="external">table 2</a>) because of their association with prognosis. (See <a class="local">'Prognostic factors'</a> above.)</p><p>Details of risk-stratified treatment for pediatric ALL/LBL are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Risk stratification'</a>.)</p><p class="headingAnchor" id="H1379976451"><span class="h2">B cell ALL/LBL</span><span class="headingEndMark"> — </span>B cell lineage is the most common category of ALL/LBL. In this lineage, the following four risk groups with different outcomes have been identified based upon initial clinical and biological risk factors and validated in a retrospective analysis of more than 6000 children with ALL/LBL [<a href="#rid5">5</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk</strong> – Children with favorable age (ie, 1 to 10 years); low WBC count (&lt;50,000/microL); favorable cytogenetic changes (eg, hyperdiploidy, <em>ETV6::RUNX1</em> rearrangement); and rapid response to treatment are in the low-risk category and have the best prognosis, with approximately 95 percent five-year event-free survival (EFS) [<a href="#rid3">3,5,120</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standard risk</strong> – Children age 1 to 10 years with low WBC count and favorable response to treatment, but without favorable cytogenetics, are considered to have standard-risk ALL/LBL with EFS of approximately 90 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk</strong> – Patients &gt;10 years, those with unfavorable cytogenetic changes, or measurable residual disease (MRD) &gt;0.01 percent at end-of induction (EOI) have high-risk ALL/LBL. Such patients who then have an inadequate response to initial therapy (persistent MRD at EOI) are considered very high-risk (see below).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Very high risk</strong> – Children with extreme hypodiploidy (≤44 chromosomes), t(9;22) (Philadelphia chromosome)/<em>BCR::ABL1</em> rearrangement, t(4;11)/<em>KMT2A</em> rearrangement, iAMP21, and/or failure to achieve complete remission (CR) at EOI are considered very high risk; in the United States, some children &gt;13 years are also included in this category. Five-year EFS was ≤45 percent [<a href="#rid5">5</a>]. Despite the adverse prognosis, subsets of these patients can be successfully treated with aggressive chemotherapy, often in combination with hematopoietic stem cell transplantation. </p><p></p><p>Treatment of B cell ALL/LBL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p class="headingAnchor" id="H1900782877"><span class="h2">T cell ALL/LBL</span><span class="headingEndMark"> — </span>The key prognostic determinant in T cell ALL/LBL is MRD response at EOI and at the end of consolidation (EOC) [<a href="#rid121">121</a>]. Age and presenting WBC count are not independently prognostic in T-ALL/LBL.</p><p>Treatment of T cell ALL/LBL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'T cell ALL/LBL'</a>.)</p><p class="headingAnchor" id="H3466592217"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119662.html" rel="external">"Society guideline links: Acute lymphoblastic leukemia"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) is the most common cancer in children. Overall, &gt;90 percent of children with ALL/LBL are cured, but some survivors experience long-term treatment-related toxicity (eg, effects on growth and development, endocrine conditions, and secondary cancers). </p><p></p><p class="bulletIndent1">Outcomes are related to certain clinical and laboratory features at the time of diagnosis and to an early response to treatment. Stratification of treatment of ALL/LBL according to prognosis enables preservation of excellent outcomes for children with favorable prognostic features, while limiting treatment-related toxicity; conversely, treatment is intensified for children with certain adverse prognostic features. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic factors</strong> – Validated adverse prognostic features include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunologic subtype </strong>– T cell immunophenotype is less common than B cell lineage and it is associated with adverse prognosis. (See <a class="local">'Immunophenotype'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytogenetic/molecular features</strong> – Chromosome changes (ie, numerical or structural abnormalities) and certain molecular abnormalities are associated with either favorable or adverse outcomes. (See <a class="local">'Cytogenetics'</a> above.) </p><p></p><p class="bulletIndent2">Examples of such features and their prognostic influence include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>High hyperdiploidy</strong> – Favorable (see <a class="local">'High hyperdiploidy'</a> above) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hypodiploidy</strong> – Adverse (see <a class="local">'Hypodiploidy'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>t(12;21)/</strong><strong><em>ETV6::RUNX1</em></strong> – Favorable or neutral (see <a class="local">'t(12;21)/ETV6::RUNX1'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>t(9;22)/</strong><strong><em>BCR::ABL1 </em></strong><strong>(Philadelphia chromosome [Ph]-positive)</strong> – Adverse (see <a class="local">'t(9;22)/BCR::ABL1'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Ph-like (</strong><strong><em>BCR::ABL1</em></strong><strong>-like) ALL/LBL</strong> – Adverse (see <a class="local">'Ph-like (BCR::ABL1-like )'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>iAMP21</strong> (intrachromosomal amplification of chromosome 21) – Adverse (see <a class="local">'iAMP21'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>11q23/</strong><strong><em>KMT2A</em></strong><strong> rearrangements</strong> – Adverse (see <a class="local">'11q23/KMT2A'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment response</strong> – Measurable residual disease (MRD) response at specified time points in treatment. (See <a class="local">'Response to treatment/MRD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Age ≤1 year or ≥10 years</strong> <strong>at diagnosis</strong> – Adverse (see <a class="local">'Age'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>White blood cell (WBC) count &gt;50,000/microL</strong> – Adverse (see <a class="local">'White blood cell count'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Central nervous system (CNS) or testicular involvement at diagnosis</strong> – Adverse (see <a class="local">'Central nervous system or testicular involvement'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification</strong> – Risk stratification for treatment of pediatric ALL/LBL varies according to clinical and laboratory features, cytogenetic/molecular findings, and immunophenotype, and response to therapy  (<a class="graphic graphic_table graphicRef71649" href="/z/d/graphic/71649.html" rel="external">table 2</a>). (See <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of pediatric ALL/LBL according to risk stratification is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges C Philip Steuber, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol 2019; 20:e142.</a></li><li><a class="nounderline abstract_t">Hunger SP, Loh ML, Whitlock JA, et al. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer 2013; 60:957.</a></li><li><a class="nounderline abstract_t">Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int 2018; 60:4.</a></li><li><a class="nounderline abstract_t">Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007; 109:926.</a></li><li><a class="nounderline abstract_t">Inaba H, Azzato EM, Mullighan CG. Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children's Research Hospital Approach. Front Pediatr 2017; 5:258.</a></li><li><a class="nounderline abstract_t">Vrooman LM, Blonquist TM, Harris MH, et al. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv 2018; 2:1449.</a></li><li><a class="nounderline abstract_t">Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet 2020; 395:1146.</a></li><li><a class="nounderline abstract_t">Brown P, Inaba H, Annesley C, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18:81.</a></li><li><a class="nounderline abstract_t">Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica 2020; 105:2524.</a></li><li><a class="nounderline abstract_t">Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14:18.</a></li><li><a class="nounderline abstract_t">Maloney KW, Shuster JJ, Murphy S, et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000; 14:2276.</a></li><li><a class="nounderline abstract_t">Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001; 113:103.</a></li><li class="breakAll">Rabin KR, Gramatges MM, Margolin JF, et al. Acute lymphoblastic leukemia. In: Principles and Practice of Pediatric Oncology, Seventh edition, Pizzo PA, Poplack DG (Eds), Wolters Kluwer, Philadelphia 2016.</li><li><a class="nounderline abstract_t">Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115:5312.</a></li><li><a class="nounderline abstract_t">Yang JJ, Cheng C, Devidas M, et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 2011; 43:237.</a></li><li><a class="nounderline abstract_t">Xu H, Cheng C, Devidas M, et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2012; 30:751.</a></li><li><a class="nounderline abstract_t">Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010; 116:4874.</a></li><li><a class="nounderline abstract_t">Clappier E, Auclerc MF, Rapion J, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 2014; 28:70.</a></li><li><a class="nounderline abstract_t">Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81:2386.</a></li><li><a class="nounderline abstract_t">Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994; 84:570.</a></li><li><a class="nounderline abstract_t">Hilden JM, Frestedt JL, Moore RO, et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). Blood 1995; 86:3876.</a></li><li><a class="nounderline abstract_t">Cimino G, Lo Coco F, Biondi A, et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood 1993; 82:544.</a></li><li><a class="nounderline abstract_t">Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30:41.</a></li><li><a class="nounderline abstract_t">Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006; 108:441.</a></li><li><a class="nounderline abstract_t">Kang H, Wilson CS, Harvey RC, et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012; 119:1872.</a></li><li><a class="nounderline abstract_t">Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003; 101:1270.</a></li><li><a class="nounderline abstract_t">Stam RW, den Boer ML, Pieters R. Towards targeted therapy for infant acute lymphoblastic leukaemia. Br J Haematol 2006; 132:539.</a></li><li><a class="nounderline abstract_t">Nagayama J, Tomizawa D, Koh K, et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood 2006; 107:4663.</a></li><li><a class="nounderline abstract_t">Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71.</a></li><li><a class="nounderline abstract_t">Dreyer ZE, Hilden JM, Jones TL, et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer 2015; 62:419.</a></li><li><a class="nounderline abstract_t">Winick N, Devidas M, Chen S, et al. Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. J Clin Oncol 2017; 35:2527.</a></li><li><a class="nounderline abstract_t">Teachey DT, Devidas M, Wood BL, et al. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol 2022; 40:2106.</a></li><li><a class="nounderline abstract_t">Winter SS, Dunsmore KP, Devidas M, et al. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol 2018; 36:2926.</a></li><li><a class="nounderline abstract_t">Hayashi RJ, Winter SS, Dunsmore KP, et al. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. J Clin Oncol 2020; 38:3062.</a></li><li><a class="nounderline abstract_t">Dunsmore KP, Winter SS, Devidas M, et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 2020; 38:3282.</a></li><li><a class="nounderline abstract_t">Greaves MF, Janossy G, Peto J, Kay H. Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br J Haematol 1981; 48:179.</a></li><li><a class="nounderline abstract_t">Kalwinsky DK, Roberson P, Dahl G, et al. Clinical relevance of lymphoblast biological features in children with acute lymphoblastic leukemia. J Clin Oncol 1985; 3:477.</a></li><li><a class="nounderline abstract_t">Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95:416.</a></li><li><a class="nounderline abstract_t">Shuster JJ, Falletta JM, Pullen DJ, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 75:166.</a></li><li><a class="nounderline abstract_t">Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21:3616.</a></li><li><a class="nounderline abstract_t">Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998; 82:600.</a></li><li><a class="nounderline abstract_t">van den Berg H, Zsiros J, Veneberg A, et al. Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia. Med Pediatr Oncol 1998; 30:46.</a></li><li><a class="nounderline abstract_t">Gottardo NG, Hoffmann K, Beesley AH, et al. Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol 2007; 137:319.</a></li><li><a class="nounderline abstract_t">Winter SS, Jiang Z, Khawaja HM, et al. Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2007; 110:1429.</a></li><li><a class="nounderline abstract_t">Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10:147.</a></li><li><a class="nounderline abstract_t">Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1:75.</a></li><li><a class="nounderline abstract_t">Liu Y, Easton J, Shao Y, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 2017; 49:1211.</a></li><li><a class="nounderline abstract_t">Gianni F, Belver L, Ferrando A. The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia. Cold Spring Harb Perspect Med 2020; 10.</a></li><li><a class="nounderline abstract_t">Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269.</a></li><li><a class="nounderline abstract_t">Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006; 103:18261.</a></li><li><a class="nounderline abstract_t">Herranz D, Ambesi-Impiombato A, Palomero T, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med 2014; 20:1130.</a></li><li><a class="nounderline abstract_t">Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994; 84:4038.</a></li><li><a class="nounderline abstract_t">Coustan-Smith E, Conter V. Closing the circle for ETP ALL. Blood 2023; 142:2039.</a></li><li><a class="nounderline abstract_t">Wood BL, Devidas M, Summers RJ, et al. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood 2023; 142:2069.</a></li><li><a class="nounderline abstract_t">Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 2014; 166:421.</a></li><li><a class="nounderline abstract_t">Allen A, Sireci A, Colovai A, et al. Early T-cell precursor leukemia/lymphoma in adults and children. Leuk Res 2013; 37:1027.</a></li><li><a class="nounderline abstract_t">Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009; 144:147.</a></li><li><a class="nounderline abstract_t">Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11:429.</a></li><li><a class="nounderline abstract_t">Heerema NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (&gt; 50 chromosomes). J Clin Oncol 2000; 18:1876.</a></li><li><a class="nounderline abstract_t">Chauvenet AR, Martin PL, Devidas M, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood 2007; 110:1105.</a></li><li><a class="nounderline abstract_t">Rubnitz JE, Wichlan D, Devidas M, et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2008; 26:2186.</a></li><li><a class="nounderline abstract_t">Dastugue N, Suciu S, Plat G, et al. Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood 2013; 121:2415.</a></li><li><a class="nounderline abstract_t">Sutcliffe MJ, Shuster JJ, Sather HN, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. Leukemia 2005; 19:734.</a></li><li><a class="nounderline abstract_t">Pui CH, Carroll AJ, Head D, et al. Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood. Blood 1990; 76:590.</a></li><li><a class="nounderline abstract_t">Raimondi SC, Zhou Y, Shurtleff SA, et al. Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genet Cytogenet 2006; 169:50.</a></li><li><a class="nounderline abstract_t">Carroll AJ, Shago M, Mikhail FM, et al. Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. Cancer Genet 2019; 238:62.</a></li><li><a class="nounderline abstract_t">Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110:1112.</a></li><li><a class="nounderline abstract_t">Safavi S, Paulsson K. Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis. Blood 2017; 129:420.</a></li><li><a class="nounderline abstract_t">Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45:242.</a></li><li><a class="nounderline abstract_t">Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9:1985.</a></li><li><a class="nounderline abstract_t">Sun C, Chang L, Zhu X. Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse. Oncotarget 2017; 8:35445.</a></li><li><a class="nounderline abstract_t">Becker M, Liu K, Tirado CA. The t(12;21)(p13;q22) in Pediatric B-Acute Lymphoblastic Leukemia: An Update. J Assoc Genet Technol 2017; 43:99.</a></li><li><a class="nounderline abstract_t">Jones LK, Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 2005; 130:489.</a></li><li><a class="nounderline abstract_t">Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 2014; 28:1467.</a></li><li><a class="nounderline abstract_t">Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10:125.</a></li><li><a class="nounderline abstract_t">Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470.</a></li><li><a class="nounderline abstract_t">Loh ML, Zhang J, Harvey RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood 2013; 121:485.</a></li><li><a class="nounderline abstract_t">Tran TH, Loh ML. Ph-like acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016; 2016:561.</a></li><li><a class="nounderline abstract_t">Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 2016; 111:784.</a></li><li><a class="nounderline abstract_t">Moorman AV, Robinson H, Schwab C, et al. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol 2013; 31:3389.</a></li><li><a class="nounderline abstract_t">Heerema NA, Carroll AJ, Devidas M, et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. J Clin Oncol 2013; 31:3397.</a></li><li><a class="nounderline abstract_t">Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359:1909.</a></li><li><a class="nounderline abstract_t">Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004; 18:521.</a></li><li><a class="nounderline abstract_t">Winters AC, Bernt KM. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr 2017; 5:4.</a></li><li><a class="nounderline abstract_t">Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Hematology Am Soc Hematol Educ Program 2017; 2017:13.</a></li><li><a class="nounderline abstract_t">Wood B, Wu D, Crossley B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 2018; 131:1350.</a></li><li><a class="nounderline abstract_t">Gaipa G, Cazzaniga G, Valsecchi MG, et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica 2012; 97:1582.</a></li><li><a class="nounderline abstract_t">Irving J, Jesson J, Virgo P, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica 2009; 94:870.</a></li><li><a class="nounderline abstract_t">Malec M, van der Velden VH, Björklund E, et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia 2004; 18:1630.</a></li><li><a class="nounderline abstract_t">Ryan J, Quinn F, Meunier A, et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol 2009; 144:107.</a></li><li><a class="nounderline abstract_t">Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood 2015; 126:964.</a></li><li><a class="nounderline abstract_t">Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118:2077.</a></li><li><a class="nounderline abstract_t">Pui CH, Pei D, Raimondi SC, et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia 2017; 31:333.</a></li><li><a class="nounderline abstract_t">O'Connor D, Enshaei A, Bartram J, et al. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol 2018; 36:34.</a></li><li><a class="nounderline abstract_t">Rau RE, Dai Y, Devidas M, et al. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 2021; 68:e28929.</a></li><li><a class="nounderline abstract_t">van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352:1731.</a></li><li><a class="nounderline abstract_t">Cavé H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591.</a></li><li><a class="nounderline abstract_t">Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008; 111:5477.</a></li><li><a class="nounderline abstract_t">Berry DA, Zhou S, Higley H, et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol 2017; 3:e170580.</a></li><li><a class="nounderline abstract_t">Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 2013; 14:199.</a></li><li><a class="nounderline abstract_t">Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107:1116.</a></li><li><a class="nounderline abstract_t">Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113:4153.</a></li><li><a class="nounderline abstract_t">Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2010; 148:80.</a></li><li><a class="nounderline abstract_t">Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351:550.</a></li><li><a class="nounderline abstract_t">Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99:4386.</a></li><li><a class="nounderline abstract_t">Laughton SJ, Ashton LJ, Kwan E, et al. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2264.</a></li><li><a class="nounderline abstract_t">Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343:196.</a></li><li><a class="nounderline abstract_t">Nyvold C, Madsen HO, Ryder LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99:1253.</a></li><li><a class="nounderline abstract_t">Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100:52.</a></li><li><a class="nounderline abstract_t">Conter V, Valsecchi MG, Parasole R, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood 2014; 123:1470.</a></li><li><a class="nounderline abstract_t">Mullighan CG, Jeha S, Pei D, et al. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood 2015; 126:2896.</a></li><li><a class="nounderline abstract_t">Goulden N, Bader P, Van Der Velden V, et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122:24.</a></li><li><a class="nounderline abstract_t">Pui CH, Pei D, Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol 2015; 16:465.</a></li><li><a class="nounderline abstract_t">Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002; 87:154.</a></li><li><a class="nounderline abstract_t">Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000; 14:2205.</a></li><li><a class="nounderline abstract_t">Visser JH, Wessels G, Hesseling PB, et al. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001; 18:187.</a></li><li><a class="nounderline abstract_t">Roy A, Bradburn M, Moorman AV, et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005; 129:35.</a></li><li><a class="nounderline abstract_t">Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27:5168.</a></li><li><a class="nounderline abstract_t">Moorman AV, Richards SM, Martineau M, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood 2003; 102:2756.</a></li><li><a class="nounderline abstract_t">Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016; 2016:580.</a></li></ol></div><div id="topicVersionRevision">Topic 6248 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30842058" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23255467" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29143423" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment and biology of pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003380" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29255701" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children's Research Hospital Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29941458" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32247396" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31910389" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33054110" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558195" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11187919" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328289" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328289" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20139093" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21297632" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22291082" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20699438" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064621" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8481519" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8025282" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579356" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329709" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731795" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16556894" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22210879" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406912" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16445826" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Towards targeted therapy for infant acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16478880" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18287387" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cancer statistics, 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25399948" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28535084" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35271306" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30138085" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32552472" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32813610" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7016165" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872347" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical relevance of lymphoblast biological features in children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10627444" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1688495" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512392" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9452280" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371389" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17456054" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17495134" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147408" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12086890" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28671688" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31570389" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472075" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114293" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25194570" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7994022" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38095922" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Closing the circle for ETP ALL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37556734" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24708207" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23827350" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Early T-cell precursor leukemia/lymphoma in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19006567" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20409752" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10784628" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (&gt;50 chromosomes).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442849" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445843" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23321258" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15789069" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2378987" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16875937" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425927" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17473063" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27903530" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334668" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The genomic landscape of hypodiploid acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609706" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418909" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28809761" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The t(12;21)(p13;q22) in Pediatric B-Acute Lymphoblastic Leukemia: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098062" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Philadelphia positive acute lymphoblastic leukaemia of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24441288" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138562" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129520" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23212523" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913529" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Ph-like acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27473820" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940220" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940221" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12057554" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14712291" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232907" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222232" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29284596" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22581001" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19377076" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295608" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016726" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124497" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719599" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27560110" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29131699" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33559396" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848348" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9718378" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18388178" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28494052" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23395119" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16195338" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19141862" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19863538" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9492773" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12036866" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800317" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904666" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830473" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12070008" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24415536" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26527677" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823342" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25800893" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836166" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11187912" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11293286" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15801953" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805690" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829593" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913532" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : T-cell acute lymphoblastic leukemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
